Advertising Rules for Aesthetics: What You Can and Can't Say About Botox

July 15, 2026

Key points

Botulinum toxin is a prescription-only medicine and cannot be advertised to the public, in any form, direct or implied.
The same rule covers other POMs commonly promoted: hyaluronidase (dissolving), triamcinolone or Kenalog (hayfever injections) and injectable B12.
Indirect wording such as “anti-wrinkle” or “tox”, hashtags, and ordinary public social posts all count as advertising.
Fillers are medical devices and can currently be advertised within the accuracy rules. Breaching the POM rules can mean takedowns, regulator referral and criminal penalties.

Few areas of aesthetic practice cause more quiet anxiety than advertising, and with good reason. Almost every new practitioner has seen busy clinics openly promoting “Botox from £99” on Instagram, assumed that must be allowed, and then heard a rumour that it is in fact against the rules. Both things are true at once: it happens constantly, and it is not permitted. The gap between common practice and the actual rules is wider here than almost anywhere else in aesthetics, which is exactly why so many well-meaning practitioners breach the rules without ever intending to. This guide sets out the position calmly so you can market your work with confidence rather than crossing a line you did not know was there.

The stakes have risen recently. The Advertising Standards Authority (ASA) and the Committee of Advertising Practice (CAP) have made enforcement in this area a priority, and from early 2025 began using new monitoring technology to find offending posts on social media automatically rather than waiting for a complaint. In other words, the era of assuming nobody is looking is over. The good news is that the rules, once you understand them, are not difficult to work within, and staying compliant tends to make your marketing more credible rather than less.

This guide is for every practitioner who advertises, whether you come from a medical background as a nurse, doctor, dentist or prescriber, or from a non-medical route. The advertising rules apply to you based on what you promote and where, not on your professional title, so they are relevant to everyone.

The one rule that explains almost everything

The single most important thing to understand is this: botulinum toxin is a prescription-only medicine (POM), and under the advertising codes, prescription-only medicines cannot be advertised to the public at all. This is the rule from which almost everything else follows.

The relevant provision is CAP Code rule 12.12, which prohibits the advertising of prescription-only medicines to the public. It is not specific to aesthetics; it applies to all POMs. Botox is simply the most visible example because it is marketed so heavily in a consumer setting. The brand names you will recognise, Botox, Bocouture, Azzalure, Dysport and others, are all botulinum toxin products, and all are prescription-only. That means none of them can be named or promoted in advertising directed at the public, regardless of how the treatment is priced, packaged or described.

This surprises people because it feels counterintuitive. Surely a legal treatment that thousands of clinics offer can be advertised? The answer is that the treatment can be provided lawfully, and a patient can be given information about it once they are in a proper clinical conversation, but it cannot be promoted to the public at large through advertising. The restriction is about protecting the public from being encouraged to seek a prescription medicine, not about whether the treatment itself is legitimate.

It is not only Botox: other prescription-only medicines caught by the same rule

Because the rule is about prescription-only medicines in general, it reaches well beyond botulinum toxin, and several other injectables commonly promoted in aesthetic and wellness settings fall under exactly the same prohibition. It is worth naming the ones you are most likely to see advertised, because their very familiarity can create a false sense that they are fair game.

Hyaluronidase, the enzyme used to dissolve hyaluronic acid filler, is a prescription-only medicine, so “filler dissolving” or “dissolving” treatments cannot be advertised to the public any more than toxin can. Triamcinolone, widely known by the brand name Kenalog and frequently marketed as a “hayfever injection”, is prescription-only, so promoting it to the public is a breach. Injectable vitamin B12 (hydroxocobalamin), the basis of the popular “B12 injection” and “energy boost” adverts, is likewise a prescription-only medicine and is caught in the same way. The same logic extends to other POMs that appear in this space, such as prescription weight-loss injections, which the regulators have specifically warned must not be advertised to the public.

The unifying principle is simple: if a treatment relies on a prescription-only medicine, it cannot be advertised to the public, whatever it is called and however routine it has come to seem. The sheer number of clinics openly promoting these treatments does not make it lawful; it simply means a great many of them are in breach.

What counts as “advertising to the public”

Practitioners often assume advertising means a paid advert. The ASA’s interpretation is much broader, and this is where most breaches happen without any bad intent.

Your public-facing social media accounts count. An Instagram post, a story, a reel, a Facebook page, a TikTok video, a pinned highlight: if it is visible to the public and it promotes your services, the ASA treats it as advertising. Your website counts. Your Google listing, your email newsletters and your paid digital adverts all count. Even a hashtag can count. The ASA has been explicit that referencing botulinum toxin in a publicly accessible post, including through hashtags, is likely to be seen as an implied advertisement for a prescription-only medicine.

The practical consequence is significant. It means you cannot simply have a normal clinic Instagram account that mentions your toxin treatments, because that account is, in advertising terms, a shop window open to the public. The restriction is not limited to slick paid campaigns; it reaches the everyday content that most clinics post without a second thought.

The words and phrases that quietly break the rules

Because the rule captures implied promotion as well as direct naming, a whole vocabulary of everyday aesthetic marketing language falls foul of it. This is the part most worth reading closely, because these are the exact phrases that get sincere practitioners into trouble.

The ASA treats indirect references to botulinum toxin as breaches just as it does the brand names themselves. That includes descriptive terms such as “anti-wrinkle injections”, “wrinkle-relaxing injections”, “wrinkle-smoothing treatment”, and playful coinages such as “beautox” or simply “tox”. If a reasonable person would understand the phrase to mean botulinum toxin, using it in public advertising is treated as advertising a POM. The same applies to imagery and context that make the meaning obvious, such as before-and-after photographs of frown lines captioned in a way that clearly points to toxin, or emojis and euphemisms used as a knowing shorthand.

The reason this matters is that many practitioners believe they are being compliant by avoiding the word “Botox” specifically, while freely using “anti-wrinkle treatment” in its place. That is not a workaround; the ASA regards it as the same breach. The safest mental test is not “have I avoided the brand name” but “would an ordinary member of the public reading this understand that I am promoting a toxin treatment”. If the answer is yes, it is likely to be a breach.

Why fillers are different, and why that could change in future

One of the most useful distinctions to hold clearly is that dermal fillers are not treated the same way as botulinum toxin, because they are regulated differently. Most dermal fillers are currently classified as medical devices rather than medicines, and they are not prescription-only. That means fillers can currently be advertised to the public, provided the advertising follows the general rules that apply to all marketing: claims must be accurate and not misleading, they must be capable of substantiation, and they must be socially responsible. You can name filler treatments and, within those limits, show results, which you cannot do with toxin.

This distinction is genuinely important and often misunderstood, so it is worth stating plainly: the rules differ because the products are regulated under different legal frameworks, one as a prescription medicine and the other as a medical device. It is not that fillers are unregulated or that anything goes. Misleading claims, unrealistic before-and-after imagery, and pressure-selling around fillers can all still breach the rules, and fillers carry serious clinical risks of their own.

It is also worth knowing that this landscape is slowly moving. Following its 2022 consultation on the future regulation of medical devices, the Medicines and Healthcare products Regulatory Agency (MHRA) confirmed its intention to bring products that are marketed for a purely aesthetic purpose but function like medical devices, dermal fillers among them, within the scope of the UK medical device regulations. You can read this in the government’s consultation outcome on the scope of the regulations. That intention has since been carried forward rather than dropped: the MHRA’s roadmap for the future regulation of medical devices, first published in 2024 and updated since, continues to list products without a medical purpose, such as dermal fillers, among the reforms being introduced in phases through new regulations.

Two things are worth holding in mind about this. First, the filler-specific changes are not yet in force, and the timelines have moved more than once, so for now dermal fillers remain regulated exactly as they are today. Second, this is about regulating fillers more tightly as medical devices, not about making them prescription-only, because the prescription-only concept generally applies to medicines rather than devices. The direction of travel is nonetheless towards more scrutiny, not less, so building careful, honest advertising habits around fillers now is a sound investment even while the current rules remain more permissive than those for toxin.

What you genuinely can do

At this point it would be easy to feel that you cannot advertise at all, but that is not the case. Plenty of effective, compliant marketing is available to you, and clinics that market well within the rules often build more trust precisely because their content is educational rather than promotional.

You can promote your clinic, your brand and your professionalism. You can advertise a consultation, because you are offering an assessment and a conversation, not promoting a specific prescription medicine. You can talk in general terms about the concerns you help with, such as facial ageing, confidence or skin health, without naming or implying a POM. You can advertise treatments that are not prescription-only, including many skin treatments and, subject to the general rules on accuracy, dermal fillers. You can publish genuinely educational content that informs the public about safety, aftercare and how to choose a practitioner, which is often the most valuable content of all. And once a patient has made contact and is in a private, individualised clinical discussion, you can give them full and frank information about toxin treatments, because that is a consultation rather than an advertisement to the public.

The mindset that keeps you safe is to market the outcome and the experience rather than the prescription product. “Confident, refreshed skin, tailored to you, from a practitioner who puts safety first” is compliant and appealing. “Anti-wrinkle injections, three areas for £150” is neither.

But everyone lists their prices online. Can I put Botox on my booking page?

This is one of the most common practical questions, and the answer is more nuanced than a flat yes or no. You cannot promote botulinum toxin to the public, but the ASA does accept that a website may include a price list that happens to list a POM such as Botox, provided it is genuinely a neutral price list rather than a piece of promotion. In other words, placement and context are what decide it, which is close to the instinct many practitioners already have.

In practice, the ASA’s guidance means a Botox price entry can be acceptable only if it meets several conditions together. It should not appear on your homepage, and there should be no direct “Prices” link from the homepage that leads straight to Botox pricing. It should carry no product claims, and nothing that encourages a visitor to choose the treatment because of the price, which rules out offers, discounts and “from £X” style deals. And it should not be something a casually browsing consumer comes across easily: the accepted model is that a visitor reaches the price list only after passing through a page that promotes a consultation. A bare, factual price sitting behind a consultation page is treated very differently from a headline price or offer on your landing page.

So your instinct is broadly right, with an important refinement: it is not simply “anywhere but the homepage”. A plain price, kept off the homepage, free of claims and offers, and reachable only after a consultation-focused page, can be acceptable; anything that looks like promotion, whether that is a price on the homepage, a discount, a claim, or an easily found “Botox £X”, is not. If you would rather avoid the judgement calls altogether, making the bookable item a consultation and reserving toxin pricing for the private consultation keeps you comfortably clear of the line.

A note for non-prescribers

If you are not a prescriber, including if you are a non-medical practitioner, there is an additional point to keep in mind. Your advertising must not imply that you can prescribe or supply prescription-only medicines yourself, because you cannot. Botulinum toxin can only be prescribed by an appropriate prescriber who has assessed the patient, and non-prescribing practitioners work alongside a prescriber rather than holding or supplying the medicine themselves. Marketing that suggests otherwise is not only an advertising problem but a medicines-law and governance problem. Being transparent about how your prescribing arrangements work is both more compliant and more reassuring to patients. You can read more about where this fits into your wider systems in our beginner’s guide to clinical governance.

What actually happens if you are caught

It is tempting to treat these rules as theoretical because so many clinics appear to ignore them. That is a risky assumption, and it is worth understanding what enforcement actually looks like, because it works on more than one level.

In most cases the first thing that happens is not a fine but a demand to take the content down. The ASA, or the MHRA, will typically contact the advertiser and require the offending material to be removed, and the majority of cases are resolved at this informal stage. The ASA has publicly committed to tackling illegal toxin advertising and, as noted, now uses monitoring technology that proactively identifies offending social media posts rather than waiting for a complaint. Its sanctions include having your ads removed, being named publicly on the ASA website, having paid search and social ads taken down, and referral onwards if you do not comply.

Behind that sits a genuine legal backstop that many practitioners do not realise exists. Advertising a prescription-only medicine to the public is a criminal offence under the Human Medicines Regulations 2012, enforced by the MHRA through the criminal law. The maximum penalties are serious: an unlimited fine and, for individuals, up to two years’ imprisonment, and company directors and senior staff can be held personally liable where an offence is committed with their consent, connivance or neglect. Prosecutions are relatively uncommon precisely because most cases are settled by removal, but uncommon is not the same as impossible, and the existence of criminal liability is exactly why this should not be treated as a harmless grey area.

There is a third consequence that can matter most of all to your livelihood. Breaches can be referred to your professional regulator. For registered healthcare professionals, that can mean a referral to the GMC, NMC or GDC, where an advertising breach can feed into fitness-to-practise considerations. In short, an advertising misstep is not a minor marketing issue; it can become a financial, legal and professional one all at once.

None of this should frighten you into silence. It should simply reframe compliant advertising as part of practising professionally, in the same way that good consent and good documentation are. Practitioners who market carefully are not at a disadvantage; they are protecting the reputation that their business ultimately depends on.

Putting it into practice

The most reliable way to stay on the right side of the rules is to build a simple habit of checking your content before it goes out. Ask whether anything in the post, caption, hashtag or image would lead an ordinary person to understand that you are promoting botulinum toxin. Ask whether any claim you have made about a filler or skin treatment is accurate and something you could evidence. Ask whether your content implies you can prescribe when you cannot. If you run through those questions honestly before you publish, you will avoid the overwhelming majority of breaches.

If you would like this set out as a structured, working framework rather than a set of principles to remember, our Governance and Readiness Bundle brings advertising compliance together with the other pillars of a defensible practice, so your marketing sits within a coherent system rather than being managed post by post. For a plain-English overview of the wider regulatory picture, including where advertising fits alongside the coming licensing changes, our free UK Aesthetics Regulation Guide 2026 is a straightforward place to start.

The bottom line

Advertising rules in aesthetics feel confusing mainly because so much of the market openly breaks them. Once you hold the core principle clearly, that botulinum toxin is a prescription-only medicine and cannot be promoted to the public in any form, direct or implied, the rest becomes manageable. Market your clinic, your consultations, your expertise and your non-prescription treatments; talk about toxin only within genuine clinical conversations; keep your filler claims honest; and check every post against a simple test before it goes live. Do that, and you can promote your practice with genuine confidence, knowing that your marketing reflects the same care you bring to the treatment couch.

Frequently asked questions

Can I advertise Botox on my Instagram or website? No. Botulinum toxin is a prescription-only medicine, and prescription-only medicines cannot be advertised to the public under CAP Code rule 12.12. Your public social media accounts and website are treated as advertising, so naming or promoting toxin there is a breach.

Is it fine if I just say “anti-wrinkle treatment” instead of “Botox”? No. The ASA treats indirect references such as “anti-wrinkle injections”, “wrinkle-relaxing treatment”, “beautox” or “tox” as implied advertising of a prescription-only medicine. If a reasonable person would understand you to mean toxin, it is treated the same as naming the brand.

Can I advertise dermal fillers? Currently, yes, within limits. Most dermal fillers are regulated as medical devices rather than prescription-only medicines, so they can be advertised to the public provided your claims are accurate, not misleading and capable of substantiation. This may become more tightly regulated as the MHRA extends its oversight of fillers.

What can I safely promote? You can advertise your clinic, your consultations, your professionalism, general concerns you help with, non-prescription treatments and (carefully) fillers, and educational safety content. You can discuss toxin fully with a patient during a private, individual consultation, which is different from advertising to the public.

Is it only Botox that can’t be advertised? No. The rule covers all prescription-only medicines. Other injectables commonly promoted in this space are also prescription-only, including hyaluronidase (filler dissolving), triamcinolone or Kenalog (marketed as “hayfever injections”), injectable vitamin B12, and prescription weight-loss injections. None of these can be advertised to the public.

Can I list my Botox prices on my website or booking page? A careful price list can be acceptable, but not prominently. The ASA does not allow Botox pricing on your homepage, alongside any claims, or with any offer or promotion, and a casual browser should not come across it easily. A plain price that a visitor only reaches after a page promoting a consultation can be acceptable. If you would rather not make fine judgements, price a consultation instead and discuss toxin pricing privately.

Are there fines for advertising Botox? Yes, potentially. Most cases are resolved when the ASA or MHRA requires the content to be removed, but advertising a POM to the public is a criminal offence under the Human Medicines Regulations 2012, carrying up to an unlimited fine and up to two years’ imprisonment. Breaches can also be referred to your professional regulator.

This article is general governance and best-practice guidance for UK aesthetic practitioners and does not constitute legal or regulatory advice. Advertising rules are enforced by the ASA and CAP and are subject to change, and medicines and medical devices are regulated by the MHRA. Always check the current CAP Code and ASA guidance, and confirm your position where needed, before publishing marketing that touches on medicines or medical devices.